(MedPage Today) — The FDA has once again approved belantamab mafodotin (Blenrep) for multiple myeloma, 3 years after the drug left the market over questions about its efficacy.
A B-cell maturation antigen (BCMA)-targeted drug, belantamab mafodotin…
Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/118122
Author :
Publish date : 2025-10-23 21:45:00
Copyright for syndicated content belongs to the linked Source.
